Market Overview

UPDATE: Burrill Initiates Sangamo Biosciences at Market Outperform

Share:
Related SGMO
12 Biggest Mid-Day Gainers For Tuesday
15 Stocks Moving In Tuesday's Pre-Market Session
CSL Behring's long-acting hemophilia B treatment Idelvion approved in Japan (Seeking Alpha)

Burrill initiated coverage on Sangamo Biosciences (NASDAQ: SGMO) with a Market Outperform rating and a $28.00 price target.

Burrill noted, "We believe Sangamo's innovative genome editing approach could provide novel and transformative therapeutics, which could revolutionize the treatment of genetic disorders. … We believe there is a significant upside to our valuation, given the additional opportunities embedded in the platform, not to mention ex-U.S. markets, which aren't included in our calculation."

Sangamo Biosciences closed at $8.82 on Friday.

Latest Ratings for SGMO

DateFirmActionFromTo
Aug 2016Janney CapitalDowngradesBuyNeutral
Dec 2015Janney CapitalInitiates Coverage onBuy
Dec 2015Wells FargoInitiates Coverage onOutperform

View More Analyst Ratings for SGMO
View the Latest Analyst Ratings

Posted-In: BurrillAnalyst Color Initiation Analyst Ratings

 

Related Articles (SGMO)

View Comments and Join the Discussion!